Business Context and Reporting Period
Company: DarioHealth Corp. (DRIO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: DarioHealth is a vertically integrated health intelligence platform offering FDA-cleared hardware, AI-driven analytics, and behavioral coaching for chronic care management (diabetes, hypertension, weight management, behavioral health, and musculoskeletal pain). The company operates a B2B2C model serving employers, health plans, and pharmaceutical companies, alongside a direct-to-consumer (D2C) channel. In 2025, the company completed the integration of its 2024 acquisition of Twill, Inc., and executed a 20-for-1 reverse stock split in August 2025.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Total Revenue | $22,359 | $27,040 |
| Gross Profit | $12,665 | $13,267 |
| Gross Margin | 56.6% | 49.1% |
| Operating Loss | $(36,655) | $(57,744) |
| Net Loss | $(41,714) | $(42,747) |
| Net Loss Attributable to Common Stockholders | $(61,735) | $(40,982) |
| Cash and Cash Equivalents (Dec 31, 2025) | $21,803 | $27,764 |
| Short-term Bank Deposits | $4,214 | $697 |
| Total Debt (Long-term Loan) | $30,747 | $23,472 |
| Accumulated Deficit | $(452,078) | $(390,343) |
Note: The increase in Net Loss Attributable to Common Stockholders in 2025 compared to 2024 is primarily due to a $20.0 million deemed dividend related to preferred stock modifications and conversions.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 17.3% to $22.4 million, primarily due to the non-renewal of a significant customer acquired through the Twill acquisition. Commercial B2B2C revenue dropped from $20.0 million to $14.3 million, while Consumer revenue increased slightly to $8.1 million.
- Improved Gross Margin: Gross margin expanded to 56.6% from 49.1%, driven by lower amortization of acquired technology, reduced hosting costs, and lower payroll expenses allocated to cost of revenues.
- Operating Expense Reduction: Total operating expenses decreased significantly from $71.0 million to $49.3 million.
- R&D: Decreased 43% to $13.8 million due to post-merger integration efficiencies.
- Sales & Marketing: Decreased 23% to $20.3 million due to reduced headcount and payroll.
- G&A: Decreased 26% to $15.2 million, largely due to lower stock-based compensation and the absence of acquisition costs incurred in 2024.
- Debt Refinancing: In April 2025, the company refinanced its Avenue Loan Facility with a new $50 million Callodine Loan Facility, drawing $32.5 million. The Avenue facility was repaid in full.
- Equity Activity: The company raised approximately $17.5 million in September 2025 via a common stock and pre-funded warrant offering. All outstanding Series A-1, B-1, C, C-1, C-2, D, D-1, D-2, and D-3 Preferred Stock was converted to common stock or pre-funded warrants by September 2025.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Liquidity: Management believes current cash and cash equivalents ($26.0 million total liquid assets) are sufficient to fund operations for at least the next 12 months. The company expects to continue generating losses until it achieves profitability through commercialization.
- Strategic Review: In September 2025, the Board initiated a strategic review following unsolicited inbound expressions of interest. A Special Committee was formed to evaluate potential opportunities, including a sale, merger, or continued execution of the current strategy.
- Growth Drivers: The company is focusing on bundled full-suite offerings, GLP-1 medication support programs, and expanding its employer footprint (167 employer customers in 2025, up from 53 in 2024).
- AI Initiatives: Launched "DarioIQ" (AI layer for member experience) and "DarioSHIFT" (AI agents for operational efficiency) in late 2025.
Key Risks & Contingencies:
- Capital Requirements: The company has a history of losses and will require additional capital to fund operations and growth. Failure to secure financing could lead to business failure.
- Debt Covenants: The Callodine Loan Facility includes financial covenants. The company experienced a covenant breach in August 2025 but utilized an Equity Cure and subsequently amended the agreement in November 2025 to reset covenants and waive testing for Q2 and Q3 2025.
- Geopolitical Risk: Significant operations are located in Israel. Ongoing regional conflicts and military instability pose risks to operations, supply chains, and employee availability (reserve duty).
- Regulatory & AI Risk: Risks related to FDA clearance for new devices, data privacy (HIPAA/GDPR), and the accuracy/bias of AI models (DarioIQ) are highlighted as material risks.
- Stock Listing: The company regained compliance with Nasdaq minimum bid price requirements in September 2025 following a reverse stock split, but faces immediate delisting risk if the price falls below $1.00 for 30 consecutive days.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $26 million cash position against the current burn rate and the timeline for the next capital raise.
- Debt Covenant Compliance: Monitor the company's ability to meet the amended Callodine Loan Facility covenants, specifically the $10 million minimum consolidated unencumbered liquid assets covenant.
- Strategic Review Outcome: Track the progress of the strategic review initiated in September 2025 to determine if a change of control transaction is imminent.
- Revenue Concentration: Assess the impact of the non-renewal of the major Twill customer and the company's ability to replace that revenue with new employer contracts.
- Geopolitical Exposure: Evaluate the potential disruption to operations in Israel and India due to ongoing regional conflicts.
- Preferred Stock Conversion: Confirm the full conversion of all preferred stock series and the resulting dilution impact on common shareholders.